Multiple Myeloma (MM) is a B-cell malignancy characterized by the expansion of clonal plasma blasts/plasma cells within the bone marrow (BM) that relies on multiple signaling cascades, including tyrosine kinase activated pathways, to proliferate and evade cell death. Despite emerging new treatment strategies, MM remains at present incurable. Thus, novel approaches targeting several signaling cascades by using the multi-tyrosine kinase inhibitor (TKI), sorafenib, seems a promising treatment approach for MM. Here, we demonstrate that sorafenib induces cell death in MM cell lines and in CD138+ enriched primary MM patient samples in a caspasedependent and independent manner. Furthermore, sorafenib has a strong anti-tumoral and antiangiogenic activity in the 5T33MM mouse model leading to increased overall survival. MM 
Introduction
Multiple myeloma (MM) is a neoplastic B cell disorder characterized by proliferation of malignant plasma cells in the bone marrow (BM) where they interact with the BM microenvironment leading to skeletal destruction and angiogenesis (1) . MM accounts for 1% of all malignancies and 10% of all hematological malignancies (2) . Recently introduced drugs, like thalidomide, lenalidomide, or bortezomib, in the clinic have improved survival and are therefore widely used as a first-and second-line treatment against MM. Albeit the use of these drugs, the 5-year relative survival rate has only marginally increased and MM patients eventually relapse thus further highlighting the unmet medical need for new therapeutic agents (3) (4) (5) .
MM is characterized by the activation of multiple of tyrosine kinase signaling cascades, that induce three main downstream pathways, the Raf/MEK/ERK1/2, the PI3K/AKT and the Jak/STAT3. One of the main downstream effects of these cascades is the inhibition of cell death, mainly by the overexpression of anti-apoptotic Bcl-2 family members such as Mcl-1, Bcl-2 and Bcl-xL, as well as the downregulation of pro-apoptotic BH3-only proteins such as Bim (6) (7) (8) (9) (10) .
Targeting of multiple activated tyrosine kinase signaling cascades with chemical inhibitors maybe a promising therapeutic strategy against MM. Such a multi-tyrosine kinase inhibitor (TKI) is sorafenib, a novel bi-aryl urea, a type II inhibitor primarily against Raf1, VEGFR and PDGFRβ (11) . Sorafenib is already in use in the clinic for the treatment of renal cell carcinoma and hepatocellular cancer (12) .
MM pathogenesis, proliferation and response to therapy largely depend on the BM microenvironment (13) . The complex interplay between MM cells and stromal cells involves numerous growth factors, most predominantly IGF-1 and IL-6, but also cytokines like tumor necrosis factor α (TNF-α), transforming growth factor β (TGF-β) and vascular endothelial growth factor (VEGF) which are secreted by the MM cells. These cytokines in turn may induce IL-6, insulin-like growth factor 1 (IGF-1) and platelet derived growth factor β (PDGFβ) secretion from BM stromal cells (BMSCs) (13) . Recent advances in the understanding of molecular mechanisms underlying the pathogenesis and progression of MM indicate that the use of tyrosine kinase inhibitors as single agents or used in combinatorial regimes may constitute a good therapeutic approach.
In the present study we investigated the efficacy of sorafenib as a multiple myeloma anticancer agent in cell lines, patient samples and in mice. We have found that sorafenib is a potent inducer of caspase-dependent and independent cell death even in the presence of bone marrow stroma cells. Furthermore, we found that autophagy is cytoprotective and that the usage of autophagy inhibitors such as chloroquine enhances the cytotoxic effects of sorafenib. The efficacy of sorafenib can also be improved by the combination with the Bcl-2/Bcl-xL antagonist ABT737 in inducing cell death in the MM cell lines and in primary MM samples.
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Materials and Methods
Antibodies and reagents
The pancaspase inhibitor z-VAD-FMK (z-Val-Ala-Asp(OMe)-FMK) (MP biomedicals) was used at 10 μM, 3-methyladenine (3-MA) (Sigma-Aldrich) was used at 5 mM, Necrostatin1 (Sigma-Aldrich) was used at 50 μM, chloroquine (Sigma-Aldrich) at 10 μM, ABT737 (active biochemical Co.) at 10 μM, rapamycin at 1 μM, U0126 (Sigma-Aldrich) at10 μM, MG132
(Calbiochem) at 4 µM. and G418 (Gibco) 600µg/ml. Sorafenib (Bayer HealthCare) was dissolved in DMSO and unless otherwise indicated, 10µM were used for the experiments.
The primary antibodies used in this study phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, 
Patient samples
MM BM samples were obtained from the Karolinska University Hospital Solna, Stockholm, Sweden. Patients had a confirmed diagnosis of MM and all were previously untreated except patient 7 who had a relapse and 9-10 who were previously treated with bortezomib with no particular therapeutic benefit ( Table 1 ). The study was approved by the regional ethics committee and all patients gave their informed consent in accordance with the Declaration of Paque Plus density sedimentation (Amersham Biosciences) were purified with EasySep human CD138 selection kit according to manufacturer's protocol (StemCell Technologies). The purified tumor cells were seeded at 1x10 6 cells/ml into 12-well or 48-well plates followed by immediate addition of the anti-cancer drugs.
Peripheral blood mononuclear cell isolation
One unit of buffy coat of healthy donor was purchased from Karolinska University laboratory (Karolinska Universitetslaboratoriet), then peripheral blood mononuclear cell (PBMC) were further purify by using Ficoll-Paque Plus density sedimentation (Amersham Biosciences). 2x10 
Cells lines and transfections
L88, the human BM stromal cell line has been previously described (14) . The human MM cell lines OPM-2, U-266, LP1, NCI-H929, Karpas 620 and RPMI 8226 kindly provided by Dr.
Brigitte Sola (Université de Caen, France). The bortezomib sensitive RPMI 8226 cells and resistant 8226/7B680 cell lines were provided by Dr. Javier Naval (Universidad de Zaragoza, Spain). All cell lines were authenticated by the LGC standards cell line authentication service.
The murine 5T33MMvitro cells were cultured as described previously (15) . Cells were maintained in a 37°C, 5% CO 2 , fully humidified incubator and were grown in RPMI 1640
(Hyclone, UK) supplemented with 10% fetal bovine serum (FBS, Hyclone UK), L-glutamate and antibiotics penicillin/streptomycin (Gibco). In all experiments, the cells were cultured in 6 or 12-well plates 24h prior to treatment. 
Co-culture experiments
L88 cells were plated in 6 or 12 well plate 2 hours before putting cell culture inserts (BD Falcon™) which contain MM cell lines. The cells were incubated together overnight before treatment.
Assessment of apoptosis and immunostainings for flow cytometry
Exposure of phosphatidylserine as a marker of apoptosis was assessed by Annexin V-FLUOS (Roche) (8) . Briefly, 2 x 10 5 cells per sample were collected, washed in PBS, pelleted, and resuspended in incubation buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl 2 )
containing 1% Annexin V and PI followed by analysis on fluorescence-activated cell sorter
Calibur flow cytometer (Becton Dickinson) using the Cell Quest software. To detect sorafenib changes in mitochondrial membrane potential, cell were stained with tetramethylrhodamine ethyl ester perchlorate (TMRE; Molecular Probes Inc.) as previously described (8) . To measure the pro-apoptotic activation of Bak and caspase-3, intracellular stainings were performed as previously described and measure by flow cytometry (8) .
Immunocytochemistry
The effect of sorafenib on MM cell lines was analysed by staining of mitochondria with MitoTracker (Mol. Probes, Inc.) and co staining with either active Bak antibody or cytochrome c antibody as previously described (9) . Purified MM cells (patients 1, 2, 7 and 8) were incubated with sorafenib alone or in combination with Bcl-2 antagonist (ABT 737) for 24 and 48 hours. At harvest, 10% resazurin was added followed by incubation for 2-3 h at 37°C in a humidified 5% CO 2 in-air atmosphere. The resazurin was excited at 530 nm and the emitted light was measured at 590 nm. Analysis of fluorescence was performed using Wallac Victor Multilabel Counter (Wallac, Turku, Finland).
Resazurin assay
Mean was calculated from duplicate or triplicate wells and subtracted from mean of blank wells resulting in ΔFluorescence. The relative number of viable cells was expressed as percentage of untreated control and calculated as 100 x ΔFluorescence (treated wells)/ ΔFluorescence (untreated wells).
Cell cycle analysis
We use NucleoCounter® NC-3000™ from chemometec to analyse cell cycle according to the manufacturer's specifications. One million cells were harvested and washed by PBS then resuspended in 0.5 mL Solution 10 supplemented with 10 μg/ml DAPI. Cells were incubated at 37°C for 5 minutes then 0.5 ml Solution 11 was added and 30μl of suspended cells was loaded on 2-chamber slide (NC-Slide A2™) and cell cycle was analyzed by using provided software.
Mitochondria Isolation
x 10
7 cells were harvested and mitochondria were isolated using the Mitochondria Isolation Kit (Pierce Biotechnology, USA) according to the manufacturer's specifications.
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inhibitor cocktail (Roche Diagnostics, Meylan, France). After 1h on ice, samples were sonicated and protein quantification was carried out using a Bio-Rad protein assay. Equal amounts of soluble proteins (15-30 μg) were denaturated by boiling and resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane. After blocking in 5% non-fat dry milk in PBS for 1h and probing with a specific primary antibody and a horseradish peroxidase-conjugated secondary antibody, the protein bands were detected by chemiluminescence (Supersignal, Pierce) and X-ray film exposure (Kodak).
Protein loading was normalized by using anti-GAPDH or anti-actin antibodies.
RNA extraction, cDNA and qRTPCR
The RNA was extracted using Qiagen RNeasy mini kit (Qiagen) and DNase treated (Ambion 
LA1230281).
In vivo analysis of tumor burden
To study the effects of sorafenib, on myeloma progression, two groups of C57BL/KaLwRijHsd mice (n=10) were injected i.v. with 0.5×10 6 5T33MMvv cells; one group of 10 naive mice was included as negative control. Three days after tumor cell inoculation, mice were treated with either sorafenib (daily, oral gavage, 60 mg/kg) or vehicle
(1:4 dilution of 50:50 Sigma Cremophor EL; 95% Ethanol) until the vehicle-treated 5T33MM-bearing mice showed signs of morbidity. Serum paraprotein concentration was assessed using standard electrophoretic techniques. BM tumor burden was assessed by determining plasmacytosis on cytosmears (15) . A similar experimental setup was used to assess the effects of sorafenib treatment on overall survival. Mice were treated daily and were sacrificed upon signs of morbidity. As a control for possible side-effects, we have treated naïve C57BlKaLwRij mice either with sorafenib 60 mg/kg mouse daily oral gavage or with vehicle.
21 days after treatment, mice were weighted, sacrificed and different samples taken. Peripheral blood was analyzed for white and red blood cell count; samples of skin, kidney, spleen, hart, lung and liver were fixed and haematoxylin and eosin (HE) stained sections were evaluated.
Assessment of microvessel density
Microvessel density (MVD) was determined by CD31 staining as previously described (7).
Briefly, mouse femurs were fixed in zinc fixative for 48 hours, decalcified for 48 hours, and embedded in paraffin. After blocking with normal goat serum, sections were incubated with a rat 
Results
Sorafenib induces cell death in a panel of human Multiple Myeloma cells
The panel of human cell lines, representative of MM, U-266, LP-1, OPM-2, NCI-H929, RPMI 8226 and Karpas 620 were exposed for 24h to increasing concentration of sorafenib (Sor) and the number of dead cells was measured by Annexin V (AnnV)/Propidium Iodide (PI) stainings (Fig. 1A) . Sor induced cell death in all cell lines of the panel with RPMI 8226 being the most sensitive and U-266 being the least sensitive. Treatment of the MM cell lines with 10 µM Sor for 24, 48 and 72h resulted in progressive eradication of the majority of MM cell lines tested except for the U-266 cells which maintained around 50% viability even after 72h of treatment (Fig. 1B) .
Cell cycle analysis of the MM cell lines treated with Sor revealed an accumulation of the cells in the G0/G1 phase ( Supplementary Fig. 1 ). In an attempt to characterize the mode of cell death, we examined a number of well-defined apoptotic markers ( Fig. 1 C, D, E, F and G). We found that Sor induce apoptotic cell death characterized by mitochondrial depolarization, cytochrome c release, Bak and caspase-3 activation, and nuclear condensation/fragmentation.
Sorafenib induces caspase-dependent and independent cell death
Sor-induced cell death was accompanied by activation of the effector caspases 3 and 7 in all the MM cell lines, already observed after 8h of treatment ( Fig. 2A and B) . Co-administration of the pan-caspase inhibitor zVAD.fmk with Sor led to a marked inhibition of caspase-7 activation and PARP cleavage (cl-PARP) ( 
Sorafenib induces autophagy in MM cells
Autophagy is generally considered to be a cytoprotective pathway and protects cancer cells by removing damaged organelles and providing nutrients. In this study we wanted to investigate the role of autophagy in Sorafenib-induced cell death. One of the main negative modulators of autophagy is mTOR, activation of which is characterized by the phosphorylation of one of its direct downstream target 4EBP1. Sor treatment of U266, LP-1 and RPMI 8226 cell lines led to the inhibition of 4EBP1 phosphorylation suggesting that the mTOR activity is inhibited in these cell lines (Fig 3A) . Importantly, Sor induced autophagy in LP1 and RPMI 8226 cells, in patient samples and in mice as determined by p62 degradation, LC3 lipidation and by immunofluorescence for the detection of LC3-GFP positive foci (Fig. 3A , 3B, 5G and 7D). 3E ). Together, these data indicate that sorafenib-induced autophagy is cytoprotective and inhibition of this pathway can potentiate the efficacy of Sor.
Downregulation of Mcl-1 protein levels is critical for sorafenib-induced cell death
It has been previously described that PI3K-AKT and Ras-Raf-MAPK kinase (MEK)- translational machinery (26) . Notably, treatment with Sor led to an inhibition of the phosphorylation and activation of eIF4E, a key player in the initiation of translation (Fig. 4F) .
To determine the functional importance of Mcl-1 downregulation in Sor induced cell death, we transfected OPM-2 and RPMI cells with a construct overexpressing Mcl-1. We found that it can substantially protect OPM-2 cells and partially protect RPMI 8226 cells against apoptosis here determined as exposure of PS, caspase-3 activation and PARP cleavage ( Fig. 4G and H). These data suggest that downregulation of Mcl-1 is required for the induction of Sorinduced cell death in MM cell lines.
Sorafenib induces cell death ex vivo in the presence of BM stromal cells
The efficacy of Sor ex vivo was examined in freshly isolated CD138+MM cells from newly diagnosed MM patients (Table1). The CD138+ enriched primary MM cells from patient 1 and 2
were treated with increasing concentrations of Sor for 24 and 48h, respectively. We found that Sor displayed similar effects on these primary cells as in the cell lines (Fig. 5A) . The cytotoxic effects of Sor on peripheral blood mononuclear cells (PBMC) from a healthy donor were measured by Annexin V staining and showed a 20% increase in cell death compared to control after 48h of treatment ( (Fig. 5B) .
To investigate the role of soluble factors secreted by the tumor microenvironment we used a transwell co-culturing system between L88 BM stromal cells (BMSCs) and U-266, RPMI 8226 and OPM-2 cells. Since, the effect of the stroma on MM cell survival is largely dependent on their response to IL-6, we anticipated the effects of stroma on Sor cytotoxic efficacy to be IL-6 dependent. Indeed, in the IL-6 dependent cells RPMI 8226, Sor-induced cell death was potentiated when co-cultured with BMSCs (Fig. 5C) . In contrast the Sor-induced cell death was equally efficient in the IL-6 independent U266 in mono or co-culture. Downstream of the activated receptor tyrosine kinases, a number of common signaling pathways converge, i.e. the Janus activated kinase (Jak)-signal transducer and activator of transcription (STAT), the phosphatidylinositol 3-kinase (PI3K)-AKT and the aforementioned RAF-MEK-ERK1/2 all of which were upregulated in the presence of BMSCs (Fig. 5D) . Importantly, the levels of STAT3 phosphorylation, Bcl-xL and Mcl-1 expression in the mono-and co-culture correlated well with the protection mediated by the BMSC from Sor-induced death in RPMI 8226 cells (Fig. 5D) .
The potentiation of cell death in co-culture of OPM-2 with L88 cells was associated with the inhibition of AKT phosphorylation, downregulation of Bcl-xL and the sustained expression of Bim protein levels in response to Sor (Fig. 5D ).
Having established that 10 µM Sor is equally efficient in the treatment of primary MM patient samples as was shown for the cells in the MM cell line panel, samples from 4 additional MM patients were treated in mono-culture or in BMSC co-culture with Sor for 24 and 48h and the levels of cell death were measured by performing CD138+/AnnexinV+ double stainings to immunophenotypically detect MM cells and measure cell death ( Fig. 5E and 5F ). Sor was very potent in inducing cell death in all the primary samples cultured in mono-culture. The co-culture setting, L88 cells protected the CD138+ primary MM cells from spontaneous cell death but they were still sensitive to Sor treatment ( Fig. 5E and 5F ). Due to the lack of sufficient amount of cells, samples from patients 5 and 6 were cultured only in the presence of L88 cells for 48h and we found that MM cell from patient 5 were very sensitive to Sor and fifty percent of MM cells from patient 6 died upon sorafenib treatment (Fig. 5F ). To determine whether the molecular determinants of Sor efficacy identified in MM cell lines were also found in patient samples, we treated a BM sample, ex vivo, with Sor and examined the proteins levels of Mcl-1, the cleavage of PARP and the levels of autophagy (Fig. 5G) 
ABT737 improves the efficacy of Sorafenib against MM cells in vitro and ex vivo
Together with Mcl-1, Bcl-2 and Bcl-xL constitute the major anti-apoptotic Bcl-2 proteins, known to be involved in the acquisition of resistance to therapy. The protein levels of Bcl-2 and Bcl-xL did not change win response to Sor with the exception of Bcl-xL that decreased in the OPM-2 cells (Fig. 6A) . Ectopic expression of Bcl-2 in the U-266 cells resulted in partial resistance to Sor demonstrating the importance of Bcl-2 in the protection of MM cells to Sorinduced cell death (Fig. 6B) .
Since Sor potently downregulates Mcl-1 protein levels, we hypothesized that a combination with a Bcl-2 antagonist would lead to the concomitant targeting all three major antiapoptotic proteins in MM cells and thereby potentiate the efficacy of Sor. The MM cell lines were treated with either Sor alone or in combination with ABT737 (Fig. 6C) . LP-1 and OPM-2 cells became more sensitive to Sor in the presence of ABT737, whereas NCI-H929 and Karpas 620 cell lines were as sensitive to Sor as to ABT737 alone.
The efficacy of this combination therapy was also examined in the co-culture setting with L88 and the U-266, RPMI 8226 and OPM-2 MM cell lines. Even though RPMI 8226 were not sensitive to Sor in the presence of BMSCs (Fig. 5A) , ABT737 alone or the combination with Sor with ABT737 overcame this protection and induced high levels of cell death (Fig. 6D) .
Furthermore, ABT737 potentiated the efficacy of Sor in OMP2 cells, even in the presence of L88 cells (Fig. 6D) .
Based on the efficacy observed in MM cell lines treated with the combination of Sor and ABT737, two CD138+ MM patient samples, one in relapse (patient 7) and one newly diagnosed (patient 8) were treated similarly and cell death was measured (Fig. 6E) . The combination of Sor with ABT737 showed potent efficacy in killing primary CD138+ enriched MM cells.
Collectively, these data show that this rationale-based combination is effective in the treatment of MM cells both in vitro and ex vivo. 
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Bortezomib (BTZ) is now introduced as a therapeutic modality against MM (27) . Despite its promising therapeutic effects, patients develop resistance to this proteasome inhibitor (27) (Fig 6F) . These results were recapitulated in primary MM cells from patients that have undergone treatment with BTZ and found to be non-responsive (Fig. 6G) .
In vivo therapeutic effects of Sorafenib on 5T33MM model
To investigate the efficacy of sorafenib in murine MM cells we performed a dose curve and found that it induces dose and time dependent cell death in 5T33MM cells in vitro ( Supplementary Fig. 3A) . We also examined whether the targeted signaling cascades by sorafenib in human cell lines and patient samples, were also observed in the mouse 5T33MM cell line. In agreement with our findings in the human setting we found that sorafenib inhibits ERK phosphorylation, downregulates Mcl-1 levels and induces autophagy in 5T33MM cell line and cells (Supplementary Fig. 3B ).
Having shown that Sorafenib significantly induce apoptosis in MM cells in vitro, we next examined the in vivo efficacy using the 5T33MM mouse model. C57BL/KaLwRijHsd mice inoculated with 5T33MMvv cells were either assigned to receive Sorafenib or vehicle. Mice treated with Sorafenib showed a significant (p< 0.001) increased survival (Fig. 7A) . The experiment was terminated at day 63. At that moment 4 mice of the sorafenib treated group were still alive. These mice were sacrificed at day 66. Tumor burden was ranging from 16-34% while 
mice who were terminally diseased at earlier time points had a tumor burden in the bone marrow ranging from 52-97 %, indicating that the mice at the last points had a significant reduced tumor development. These data were paralled by a similar decrease in serum M component. In another in vivo experiment, where all mice were sacrificed the day that the first vehicle mice showed signs of morbidity, a significant reduction in serum paraprotein concentrations and plasmacytosis in the BM was observed in the Sorafenib treated mice when compared to the vehicle treated mice (Fig. 7B, C) . We examined whether the sorafenib molecular targets identified in human cell lines and patient samples, were also observed in the mouse 5T33MM. In agreement with our findings in the human setting we found that sorafenib inhibits ERK phosphorylation, induces caspase activation and autophagy in Mm cells isolated from the bone marrow of the 5T33MM mice (Fig.   7D ). In the haematoxylin and eosin (H&E) stained sections of a bone marrow from a vehicletreated mouse, the 5T33 myeloma cells have massively invaded the bone marrow accompanied by rich vascular network and no residual normal haematopoiesis (Fig. 7E) . In the H&E stained section of a bone marrow of a mouse treated with sorafenib, there is almost no residual tumor present (Fig. 7E) . In the bone marrow of a myeloma bearing mouse, there is an increased microvessel density with the majority of the vessels compressed by the myeloma infiltrate.
Treatment with Sorafenib significantly decreased microvessel density (MVD) by 60% in the BM of treated 5T33MMvv mouse, compared to vehicle-treated 5T33MMvv mice ( Fig. 7F and G) .
No adverse side effects or toxicity were observed as evaluated by behavior, body weight, histological and hematological examinations (data not shown).
Discussion
Receptor and non-receptor tyrosine kinase ((R)TKs) activated signaling cascades play a vital role in the survival and proliferation of MM cells (29) . The importance of these (R)TKs for The anti-tumoral efficacy of sorafenib may also depend to the potent inhibition of VEGFR and angiogenesis. This has been previously shown for renal cell carcinoma and hepatocellular carcinoma where the anti-angiogenic effects of sorafenib were found to be partly responsible for the potent anti-tumor activity observed in the clinic (33, 34) . In the MM setting, we found that sorafenib significantly decreased microvessel density in the bone marrow of MM mice and indicating that the anti-tumoral effects of sorafenib may, at least in part, be mediated by inhibition of angiogenesis. It is thus likely that it is the combination of direct cytotoxic effects inflicted on MM cells and decreased vascularization in the bone marrow that are responsible for the therapeutic efficacy of sorafenib.
In this study we found that Sorafenib induces both caspase-dependent and caspaseindependent cell death in the majority of the MM cell lines and MM primary cells tested, results that are in agreement with a previous report (31) . Interestingly, LP-1 and OPM-2 cells, even though they exhibited all the classical characteristics of apoptosis, were not rescued by the pre- and thereby tilting the Bcl-2 rheostat towards cell death has not been previously shown. Indeed, we found that in all the MM cell lines and in primary samples tested, the combination of these two drugs had better therapeutic efficacy than treatment of sorafenib or ABT737 alone.
Importantly this combination was very effective in primary MM patient samples.
In summary, our study provides compelling evidence for the future evaluation of the multi-tyrosine kinase inhibitor, sorafenib as a new therapeutic strategy for the treatment of MM in the clinic. 
